High risk groups in cutaneous oncology: basal cell nevus syndrome, xeroderma pigmentosum and epidermodysplasia verruciformis

[1]  A. Ershow,et al.  Nonspecific immunity and head and neck cancer: blastogenesis reviewed and revisited. , 1985, Oral surgery, oral medicine, and oral pathology.

[2]  G. Seymour,et al.  The in vitro effect of retinol on human gingival epithelium. II. Modulation of Langerhans cell markers and interleukin-1 production. , 1985, The Journal of investigative dermatology.

[3]  L. Schnitzler,et al.  Etretinate and Skin Cancer Prevention , 1985 .

[4]  G. Peck.  Therapy and Prevention of Skin Cancer , 1985 .

[5]  E. Jung,et al.  A ninth complementation group in xeroderma pigmentosum, XP I. , 1985, Mutation research.

[6]  M. Seiji,et al.  Clinical and biological studies of 26 cases of xeroderma pigmentosum in Northeast District of Japan , 1984, Archives of Dermatological Research.

[7]  J. Czernielewski,et al.  In vitro effect of UV radiation on immune function and membrane markers of human Langerhans cells. , 1984, The Journal of investigative dermatology.

[8]  P. Fritsch,et al.  [Xeroderma pigmentosum: prevention of tumors with etretinate]. , 1984, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[9]  G. Murphy,et al.  Local immune response in basal cell carcinoma: characterization by transmission electron microscopy and monoclonal anti-T6 antibody. , 1983, Journal of the American Academy of Dermatology.

[10]  G. Angelini,et al.  T cell subsets and soluble immune response suppressor (SIRS) factor in skin squamous cell carcinoma. , 1983, Acta Dermato-Venereologica.

[11]  B. Bridges.  Some DNA-repair-deficient human syndromes and their implications for human health , 1981, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[12]  A. Wysenbeek,et al.  Impaired humoral and cellular immunity in xeroderma pigmentosum. , 1980, Clinical oncology.

[13]  L. Loeb,et al.  Screening for deficits in DNA repair by the response of irradiated human lymphocytes to phytohemagglutinin. , 1977, Cancer research.

[14]  J. Dupuy,et al.  A defect of cellular immunity in Xeroderma pigmentosum. , 1974, Clinical immunology and immunopathology.

[15]  A. I. Berkel,et al.  Immunological studies in children with xeroderma pigmentosum. , 1974, The Turkish journal of pediatrics.

[16]  B. Neundörfer,et al.  Xeroderma pigmentosum patients from Germany: Clinical symptoms and DNA repair characteristics , 2004, Archives of Dermatological Research.

[17]  C. Kallenberg,et al.  BASAL-CELL NEVUS SYNDROME - IMMUNE STATUS, ETRETINATE THERAPY AND ETRETINATE HEPATITIS , 1983 .

[18]  M. Kripke.  Immunobiology of UV-Radiation-Induced Skin Cancer , 1983 .

[19]  K. Wolff,et al.  The Langerhans cell. , 1983, The Journal of investigative dermatology.

[20]  J. Fraisse,et al.  Xeroderma pigmentosum et traitement au long cours par le rétinoïde aromatique. Action préventive sur les dégénérescences épithéliomateuses , 1982 .

[21]  T. The,et al.  Cell-mediated immune response in patients with bronchial carcinoma. Relation between clinical parameters and various immunological tests for immune status investigation. , 1979, Netherlands Journal of Medicine.

[22]  E. Friedberg,et al.  Human Diseases Associated with Defective DNA Repair , 1979 .

[23]  J. Nater,et al.  DNCB reactivity in patients with skin carcinoma. , 1974, Dermatologica.